pre-IPO PHARMA

COMPANY OVERVIEW

Century Therapeutics is harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. Century’s genetically-engineered, iPSC-derived immune effector cell products are designed to specifically target hematologic and solid cancers. Its commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care.


LOCATION

  • Philadelphia, PA, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://www.centurytx.com


    CAREER WEBSITE

    https://www.centurytx.com/join-us


    SOCIAL MEDIA


    INVESTORS

    bayer fujifilm-cellular-dynamics versant-ventures


    PRESS RELEASES


    Jun 1, 2021

    Century Therapeutics Adds Respected Biotech Executives to Board of Directors


    May 5, 2021

    Century Therapeutics Expands Board of Directors with Key Appointments


    Mar 3, 2021

    Century Therapeutics Completes $160 Million Series C Financing to Accelerate Development of iPSC-derived Cell Therapy Pipeline


    Feb 17, 2021

    Century Therapeutics Significantly Expands Capabilities with New Operational, Laboratory and Manufacturing Facilities in Pennsylvania and New Jersey


    Sep 16, 2020

    Century Therapeutics Announces Appointment of Michael C. Diem as Chief Business Officer


    For More Press Releases


    Google Analytics Alternative